<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01616199</url>
  </required_header>
  <id_info>
    <org_study_id>PX-866-007</org_study_id>
    <nct_id>NCT01616199</nct_id>
  </id_info>
  <brief_title>Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma</brief_title>
  <official_title>Phase 1/2 Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) in Patients With BRAF-mutant Cancer Including Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cascadian Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the phase 1 portion of the study is to determine the maximally tolerated dose&#xD;
      (MTD) or recommended dose (RD) and the safety/tolerability of PX-866 in combination&#xD;
      vemurafenib in patients with any advanced BRAF-mutant cancer.&#xD;
&#xD;
      The purpose of the phase 2 portion of the study is to compare progression free survival&#xD;
      (PFS), antitumor activity (response rate), disease control rate (DCR), and the safety and&#xD;
      tolerability of PX-866 in combination with vemurafenib vs. vemurafenib alone in patients with&#xD;
      advanced BRAF-mutant melanoma at the doses recommended from Phase 1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 / 2 open-label study of PX-866 given in combination with vemurafenib to&#xD;
      patients with BRAF-mutant cancer, including advanced melanoma.&#xD;
&#xD;
      Phase 1 will use a 3+3 dose escalation design to evaluate up to three dose levels of PX-866&#xD;
      in combination with up to two dose levels of vemurafenib in order to identify the maximal&#xD;
      tolerated dose/recommended dose (MTD/RD) of both PX-866 and vemurafenib to be used in Phase&#xD;
      2. Vemurafenib will be administered orally twice per day on days 1-28 of all cycles except&#xD;
      cycle 1, where vemurafenib will be administered on days 9-28 to allow for PK assessments).&#xD;
      PX-866 will be administered once per day on days 1-28 of each cycle.&#xD;
&#xD;
      Phase 2 will evaluate the antitumor activity and safety of PX-866 given to patients&#xD;
      randomized 2:1 to receive combination with vemurafenib at the doses recommended from Phase 1&#xD;
      compared with vemurafenib alone administered at the approved dose orally BID. All treatments&#xD;
      will be administered on a 28-day cycle.&#xD;
&#xD;
      Patients randomized to receive single-agent vemurafenib may cross-over to receive the&#xD;
      combination treatment at the time of progression. Patients will be evaluated for progression&#xD;
      approximately every 8 weeks for the initial 24 weeks and every 12 weeks thereafter. All&#xD;
      patients with stable disease (SD) or better, will receive repeat cycles until disease&#xD;
      progression (PD), unacceptable toxicity, or withdrawal of consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (phase 1)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) (phase 2)</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of PX-866 and metabolites (phase 1)</measure>
    <time_frame>44 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)(phase 2)</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)(phase 2)</measure>
    <time_frame>56 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of vemurafenib (phase 1)</measure>
    <time_frame>44 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Advanced BRAF-mutant Cancers</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Escalation of PX-866 + vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PX-866 given with vemurafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Combination PX-866 + vemurafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PX-866 given with vemurafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Single-agent vemurafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vemurafenib given as a single agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PX-866</intervention_name>
    <description>Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.&#xD;
Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.&#xD;
Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity.</description>
    <arm_group_label>Phase 1 Dose Escalation of PX-866 + vemurafenib</arm_group_label>
    <arm_group_label>Phase 2 Combination PX-866 + vemurafenib</arm_group_label>
    <other_name>PI-3K inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vemurafenib</intervention_name>
    <description>vemurafenib is a B-Raf enzyme inhibitor</description>
    <arm_group_label>Phase 1 Dose Escalation of PX-866 + vemurafenib</arm_group_label>
    <arm_group_label>Phase 2 Combination PX-866 + vemurafenib</arm_group_label>
    <arm_group_label>Phase 2 Single-agent vemurafenib</arm_group_label>
    <other_name>Zelboraf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¥ 18 years at time of consent&#xD;
&#xD;
          -  If a sexually active male or a sexually active female of child-bearing potential,&#xD;
             agrees to use a highly effective form of contraception (including birth control pills,&#xD;
             barrier device, or intrauterine device)from the time of consent 90 days following the&#xD;
             last dose of study drug&#xD;
&#xD;
          -  If female of child-bearing potential, negative pregnancy test&#xD;
&#xD;
          -  For Phase 1: must have histologically or cytologically-confirmed advanced cancer that&#xD;
             is BRAF mutation-positive (V600E or V600K) for which there is no remaining standard&#xD;
             therapy with curative potential. Patients must have disease sites amenable to biopsy.&#xD;
             For Phase 2: must have histologically or cytologically-confirmed BRAF&#xD;
             mutation-positive (V600E or V600K) advanced (defined as unresectable Stage IIIC or IV)&#xD;
             melanoma that has not been treated with a selective BRAF inhibitor&#xD;
&#xD;
          -  For Phase 1: must have measurable or non-measurable disease. For Phase 2: must have&#xD;
             measurable disease per RECIST 1.1&#xD;
&#xD;
          -  For Phase 1: no restriction on number of prior therapy regimens. For Phase 2: the&#xD;
             following restrictions on prior therapy apply: 1) must not have been treated with a&#xD;
             selective BRAF inhibitor and must not have had more than 2 prior treatment regimens&#xD;
             for advanced metastatic disease; 2) must have completed prior cytotoxic chemotherapy a&#xD;
             minimum of 4 weeks prior to starting PX-866 and/or vemurafenib (except for BCNU and/or&#xD;
             mitomycin C, which must have been completed a minimum of 6 weeks prior to starting&#xD;
             therapy). Prior biologic therapy and localized radiation therapy must have been&#xD;
             completed a minimum of 2 weeks prior to starting therapy.&#xD;
&#xD;
          -  All toxicities related to prior cancer therapies other than alopecia must have&#xD;
             resolved to Grade 1 or less&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  In the opinion of the clinical investigator, life expectancy &gt; 3 months&#xD;
&#xD;
          -  Adequate hematologic function&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Adequate cardiac function&#xD;
&#xD;
          -  Corrected QTc must be &lt;480 milliseconds&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  May not be receiving any other investigational agents&#xD;
&#xD;
          -  Active central nervous system (CNS) metastases are excluded. Patients with a history&#xD;
             of CNS metastasis, who have been treated prior to enrollment, must be stable for eight&#xD;
             weeks after completion of treatment. These patients must have undergone appropriate&#xD;
             imaging studies and currently be on a stable, lowest possible dose of steroids&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to PX-866 or vemurafenib&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to: ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Uncorrectable electrolyte abnormalities or long QT syndrome&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus&#xD;
&#xD;
          -  Pregnant, breastfeeding, or planning to become pregnant&#xD;
&#xD;
          -  Known to be human immunodeficiency virus (HIV)-positive&#xD;
&#xD;
          -  Inability to swallow pills&#xD;
&#xD;
          -  Previous treatment with a phosphatidylinositol-3-kinase (PI-3K) inhibitor&#xD;
&#xD;
          -  Any other significant medical or psychiatric condition that in the opinion of the&#xD;
             investigator renders the patient inadequate for participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <disposition_first_submitted>April 30, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 19, 2015</disposition_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PX-866</keyword>
  <keyword>BRAF-mutant cancers</keyword>
  <keyword>Advanced melanoma</keyword>
  <keyword>BRAF inhibitor</keyword>
  <keyword>Vemurafenib</keyword>
  <keyword>Zelboraf</keyword>
  <keyword>PI-3K inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

